Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Verrica Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was $95.75 Mil.
Verrica Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verrica Pharmaceuticals EV-to-EBIT Related Terms
Verrica Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Verrica Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verrica Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Verrica Pharmaceuticals's EV-to-EBIT falls into.
Verrica Pharmaceuticals's current Enterprise Value is $80.97 Mil.
Verrica Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verrica Pharmaceuticals (VRCA) has a EV-to-EBIT of -2.95 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Verrica Pharmaceuticals and its competitors. According to the industry distribution chart, Verrica Pharmaceuticals ranks #999999 out of 365 companies in the Biotechnology industry.
Is Verrica Pharmaceuticals' EV-to-EBIT too high?
Verrica Pharmaceuticals' current EV-to-EBIT is -2.95. Based on the distribution chart, Verrica Pharmaceuticals ranks #999999 out of 365 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Verrica Pharmaceuticals has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verrica Pharmaceuticals' EV-to-EBIT compare to RANI and CGTX?
According to the Biotechnology industry distribution chart, Verrica Pharmaceuticals ranks #999999 out of 365 companies for EV-to-EBIT. This places Verrica Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 15.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.65, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Verrica Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verrica Pharmaceuticals's current EV-to-EBIT is -2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verrica Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Verrica Pharmaceuticals (VRCA) is currently considered Possible Value Trap. The stock's GF Value™ is $8.77, compared to a current price of $5.28 — trading 39.8% below its estimated fair value. The current EV-to-EBIT is -2.95. Verrica Pharmaceuticals' overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Verrica Pharmaceuticals (VRCA), the current EV-to-EBIT is -2.95 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Verrica Pharmaceuticals (VRCA) Overvalued in 2026?
Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued.
The current stock price of $5.28 is trading 39.8% below its estimated GF Value™ of $8.77.
GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.
Key valuation signals for VRCA:
EV-to-EBIT: -2.95
GF Value™: $8.77 vs. price of $5.28 (39.8% below fair value)
No single metric tells the full story. See the VRCA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
47GF Score
Get the complete analysis for VRCA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRCA has been successfully added to your 
